Novo Nordisk ties up with Emcure to expand reach of weight-loss drug semaglutide in India

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand name Poviztra in India. This collaboration aims to expand access to the drug by leveraging Emcure's extensive distribution network and field force, addressing a significant need for wider reach beyond current accessibility.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bcV0lYA
via IFTTT